Speaker Name: Prof. Inzucchi Silvio, Professor of Medicine, Yale University, New Haven, United States.

Explore this session to:

• Understand the pathophysiology of T2DM and its implications for individualized therapy selection.
• Compare sequential intensification with early combination therapy for sustained HbA1c control.
• Interpret current guideline approaches integrating CV, renal, weight, and glycemic priorities in treatment decisions.
• Evaluate evidence from VERIFY and EDICT supporting early combination strategies in newly diagnosed T2DM.
• Recognize how combination therapy may improve metabolic control and long-term vascular outcomes.